Talia Oyando Opens Up About PMOS, Weight Gain and Her Decision to Use GLP-1 Medication

Talia Oyando has opened up about living with Polyendocrine Metabolic Ovarian Syndrome (PMOS), detailing how the condition affected her weight and eventually led her to seek treatment with GLP-1 medication.

Oyando shared her experience during PMOS Awareness Month, revealing that she began experiencing symptoms in her early 20s and continued to struggle with them into her 30s.

She said the symptoms eventually became difficult to manage, prompting her to explore GLP-1 medication.

“September is PMOS Awareness Month (Polyendocrine Metabolic Ovarian Syndrome), and I get a lot of people who are asking, ‘Why did I get on GLP-1?’ It is because of PMOS that I started experiencing symptoms in my early 20s through to my 30s, and it got really bad and unbearable, and that is why I got into GLP-1,” Oyando said.

Oyando on PMOS-related weight gain

According to Oyando, persistent weight gain was among the challenges she experienced while living with the condition.

She said she continued exercising and maintaining what she considered a healthy diet but still struggled to control her weight.

“The weight gain was increasing, and I was on the gym, on my diet, eating well and working out, but even as much as I was doing that, I kept adding weight,” she said.

Oyando explained that her experience eventually prompted her to consider GLP-1 medication after exercising and making dietary changes did not prevent the continued weight gain.

She said she has since found ways to manage the condition and its symptoms more effectively, although she continues to live with PMOS.

“I have lived with it well. I still live with it but am managing my symptoms and distress better now. I found something that’s worked for me,” she added.

Oyando responds to ‘shortcut’ criticism

The media personality also addressed people who may view GLP-1 medication as an easy way of managing weight.

Oyando said her decision was influenced by the difficulties she had experienced while living with PMOS and the persistent symptoms she described.

“I know a lot of people may think it’s a shortcut, but living with pain every day was not on my bingo card,” Oyando stated.

Her comments highlight the personal considerations behind her decision to use GLP-1 medication, rather than presenting it as a universal solution for weight management.

What is GLP-1?

GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone involved in regulating blood sugar, appetite and food intake.

GLP-1 receptor agonists are medicines that mimic some of the hormone’s effects. Some are approved for the treatment of type 2 diabetes, while certain medicines in the class are also approved for chronic weight management.

The medicines can reduce appetite and increase feelings of fullness, helping some people consume less food. They are generally used alongside lifestyle changes and, like other medications, may not be appropriate for everyone.

What is PMOS?

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a term used to describe a combination of reproductive, metabolic and endocrine disturbances affecting women.

Oyando’s account focuses particularly on the impact she says the condition had on her weight. She described continuing to gain weight despite exercising, eating well and following a diet, eventually prompting her to seek another approach.